Therefore, it would be of interest to evaluate both p300 and BRD4 inhibitors as therapeutic agents against T-ALL, especially T-ALL with activating NOTCH1 mutations that display high BRD4 dependency13–15. This evidence concerns the gene EP300 and acute lymphoblastic leukemia.